E2025 / Eisai - LARVOL DELTA

Developing Topics. (PubMed, Alzheimers Dement) - "E2025 specifically suppresses the EphA4 pathway via multiple modes of action, and suppresses progression of tau pathology in a transgenic tau model of AD."

Journal • Alzheimer's Disease • CNS Disorders • EPHA4

E2025, a novel anti-EphA4 antibody, enhances EphA4 cleavage, and suppresses tau pathologies in a transgenic model of AD (AAIC 2024) - "E2025 specifically suppresses the EphA4 pathway via multiple modes of action, and suppresses progression of tau pathology in a transgenic tau model of AD."

Alzheimer's Disease • CNS Disorders • EPHA4

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of E2025 in Healthy Participants (clinicaltrials.gov) - P1 | N=32 | Completed | Sponsor: Eisai Inc. | Recruiting ➔ Completed

Trial completion

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of E2025 in Healthy Participants (clinicaltrials.gov) - P1 | N=41 | Recruiting | Sponsor: Eisai Inc. | Not yet recruiting ➔ Recruiting

Enrollment open

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of E2025 in Healthy Participants (clinicaltrials.gov) - P1 | N=41 | Not yet recruiting | Sponsor: Eisai Inc.

New P1 trial